Going Against the U.S., the UK Will Accept More Chinese Clinical Data
On April 29 local time, Bloomberg published an article stating that as global dynamics shift, the UK's pharmaceutical regulatory body will accept more data from clinical trials conducted in China, aiming to accelerate new drug approval processes. Notably, this shift in stance stands in stark contrast to the approach taken by the United States.
Although the UK currently has no plan to fully accept all Chinese data, the Medicines and Healthcare products Regulatory Agency (MHRA) hopes to leverage China’s growing research depth and plans to unveil specific implementation strategies later this year.
The report notes that China is no longer merely a nation focused on generic drug development; each year, thousands of innovative drugs enter clinical development stages, with Western and European pharmaceutical companies fiercely competing for rights to the most promising drug development projects.
Lawrence Tallon, CEO of MHRA, said in an interview: “We’ve reached a point where it’s no longer viable for Western countries like ours to continue adhering to a policy of rejecting Chinese data—especially preclinical data used to initiate local clinical trials. Such a stance would ultimately cause us to miss out on some of the most promising opportunities in innovative drug development.”
Original source: toutiao.com/article/1863861435154444/
Disclaimer: The views expressed in this article are solely those of the author.